Navigation Links
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
Date:7/27/2009

iRNAs and all of our pipeline candidates have exhibited optimal activity and stability while attenuating potential off-target effects."

Prof. Di Polo commented, "In patients with glaucoma, characteristic visual field changes and vision loss are caused by the death of retinal ganglion cells. While existing therapeutics are capable of reducing IOP, none act as selective neuroprotective agents. We are encouraged by the QPI-1007 data, which suggest a neuroprotective effect on retinal ganglion cells in experimental glaucoma, presenting a major breakthrough in novel treatments for this neurodegenerative disease."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation

Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally and is utilizing the chemistry
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
2. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... to find a colored ribbon representing a disease. A pink ... color ribbon does one think of with lung cancer?, Although ... suffering from the disease, black may be the only one ... lung cancer patients, primarily smokers between the ages of 51 ... stigma often felt by these patients, the emotional toll it ...
(Date:4/17/2014)... of Canadians surveyed said they would participate in public ... of genetic conditions, only 80 per cent said they ... sequence their newborns, genomes.,Most newborns in North America have ... two of life in which a tiny amount of ... about five to 54 conditions, depending on the state ...
(Date:4/16/2014)... , STANFORD, Calif. Consider the marvel of the embryo. ... shape and function as they multiply to become the cells ... tissues of the body. , Now, in a feat of ... the complex genetic coding that allows embryonic cells to proliferate ...
(Date:4/16/2014)... fertility treatments are the leading cause of increases in ... of premature birth, these results are not inevitable, concludes ... . The article identifies six changes in policy and ... and prematurity, including expanding insurance coverage for in vitro ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... Transcept,Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, ... 2008 Merrill Lynch Global,Pharmaceutical, Biotechnology and Medical Device ... City on Tuesday, February 5, 2008 at 8:40 ... Pharmaceuticals, Inc. is a specialty pharmaceutical company,deriving significant ...
... Feel Their Overall Health Affects Their,Recovery from Schizophrenia, ... Health,America of San Diego today released results of ... in mental health settings from the,perspective of both ... both groups are aware of actions to improve ...
... Baby Products, With Information, on the Best Baby Products and Easy-To-Follow ... ... Well, NORCROSS, Georgia, January 29 BabySupply.Info, has,launched today ... opportunity to save time and,money with a shopping comparison engine for baby ...
... Cause To Support Stefanie LaRue and Her Fight to,Live, ... cancer survivor Stefanie LaRue, known nationally as the "Breast,Cancer ... breast,cancer, is being honored at a benefit concert on ... at 2701 N. Sepulveda Blvd., Los,Angeles, CA. The event, ...
... billion -- Diluted earnings per share from continuing operations increase 16,percent ... ... -- Full year Non-GAAP EPS now expected to be $3.75 ... contract, DUBLIN, Ohio, Jan. 29 Cardinal Health, a,global provider of ...
... CHICAGO, Jan. 29 Medifacts Systems, Inc. announces ... genetic test patent to Mayo,Clinic. The patented test ... of blood-related disorders. The patent is the invention ... Vicksburg, Mississippi who,was educated at Xavier University in ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 4Health News:BabySupply.Info Announces Launch of Website for New Parents 2Health News:32-Year-Old Breast Cancer Survivor, Fashion Model Featured in Benefit Concert 'Music of the Light' at Skirball Cultural Center 2Health News:32-Year-Old Breast Cancer Survivor, Fashion Model Featured in Benefit Concert 'Music of the Light' at Skirball Cultural Center 3Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 2Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 3Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 4Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 5Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 6Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 7Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 8Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 9Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 10Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 11Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 12Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 13Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 14Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 15Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 16Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 17Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 18Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 19Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 20Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 21Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 22Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 23Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 24Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 25Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 26Health News:Medifacts Systems, Inc. Grants Exclusive License for Genetic Test Patent to Mayo Clinic 2Health News:Medifacts Systems, Inc. Grants Exclusive License for Genetic Test Patent to Mayo Clinic 3
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Fla., March 22, 2011 GeNO LLC ( ... company, today announced commencement of  the PHiano Study: ... of Pulmonary Hypertension in patients with Pulmonary Arterial ... Pulmonary Fibrosis (PH-IPF) using Inhaled NITROSYL™ nitric oxide ...
... Dry, dull skin can get you down in the ... professor and chair of the department of dermatology at Wake ... AmLactin® twice a day, seven days a week to get ... clinically proven alpha-hydroxy acid, 12% lactic acid, to gently exfoliate ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3Does Your Skin Need Therapy? 2Does Your Skin Need Therapy? 3
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Inquire...
Medicine Products: